Monopar Therapeutics Inc
NASDAQ:MNPR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Monopar Therapeutics Inc
EPS (Diluted)
Monopar Therapeutics Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Monopar Therapeutics Inc
NASDAQ:MNPR
|
EPS (Diluted)
-$2
|
CAGR 3-Years
-50%
|
CAGR 5-Years
-41%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
EPS (Diluted)
$2
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-3%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
EPS (Diluted)
$6
|
CAGR 3-Years
23%
|
CAGR 5-Years
132%
|
CAGR 10-Years
-5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
EPS (Diluted)
$14
|
CAGR 3-Years
6%
|
CAGR 5-Years
3%
|
CAGR 10-Years
5%
|
|
|
Exact Sciences Corp
NASDAQ:EXAS
|
EPS (Diluted)
-$1
|
CAGR 3-Years
32%
|
CAGR 5-Years
27%
|
CAGR 10-Years
4%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
EPS (Diluted)
$15
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
Monopar Therapeutics Inc
Glance View
Monopar Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Wilmette, Illinois and currently employs 9 full-time employees. The company went IPO on 2019-12-19. The firm is primarily focused on developing therapeutics designed for cancer patients. Its product pipeline includes Validive, camsirubicin, MNPR-101, and MNPR-202. The Validive is a first-in-class mucoadhesive buccal tablet for the prevention of radiation induced severe oral mucositis (SOM) in oropharyngeal cancer patients. Its camsirubicin is a clinical stage topoisomerase II-alpha selective novel analog of doxorubicin engineered specifically to retain anticancer activity while minimizing toxic effects on the heart. Its MNPR-101 is a humanized monoclonal antibody designed to bind a specific cell surface receptor found on cancer cells, the urokinase plasminogen activator receptor (uPAR), and to interrupt several pathways required for tumor growth and progression. The MNPR-202 is an early stage camsirubicin analog for various cancers.
See Also
What is Monopar Therapeutics Inc's EPS (Diluted)?
EPS (Diluted)
-2.7
USD
Based on the financial report for Sep 30, 2025, Monopar Therapeutics Inc's EPS (Diluted) amounts to -2.7 USD.
What is Monopar Therapeutics Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-41%
Over the last year, the EPS (Diluted) growth was -49%. The average annual EPS (Diluted) growth rates for Monopar Therapeutics Inc have been -50% over the past three years , -41% over the past five years .
